ClinicalTrials.gg
Not yet recruitingNCT07806851UNISHAPE-OSA-2Updated Sep 8, 2026

UBT251 Injection Phase Ⅲ Study (OSA-PAP)

A Phase 3 interventional study of UBT251 and UBT251 in Obstructive Sleep Apnea and Obesity, sponsored by The United Bio-Technology (Hengqin) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by The United Bio-Technology (Hengqin) Co., Ltd. (part of The United Laboratories International Holdings Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

UBT251 will be compared with placebo (an inactive substance identical in appearance) to evaluate its therapeutic effect in participants with moderate-to-severe obstructive sleep apnea maintained on positive airway pressure therapy.Participants will complete the following study procedures:1. Receive once-weekly subcutaneous injections of either UBT251 or placebo for a total treatment period of 52 weeks, while remaining on stable positive airway pressure therapy;2. Undergo all examinations and tests within the visit windows specified in the trial protocol;3. Undergo assessment of the Apnea-Hypopnea Index (AHI) upon completion of the 52-week treatment period.

02

Conditions studied

  • Obstructive Sleep Apnea
  • Obesity

Keywords

  • obstructive sleep apnea
  • obesity
  • GLP-1
  • GIP
  • GCG
03

In context

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

This study's planned enrollment of 150 is above the median of 52 across 1,474 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

The United Bio-Technology (Hengqin) Co., Ltd. is the lead sponsor of 13 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18 to 75 years inclusive at the time of signing the form.
  2. Confirmed diagnosis of obstructive sleep apnea (OSA) based on the International Classification of Sleep Disorders, 3rd Edition, Text Revision (ICSD-3-TR) criteria, with a polysomnography (PSG) showing an Apnea-Hypopnea Index (AHI) ≥ 15 events/hour at screening.
  3. Participants who have received stable positive airway pressure (PAP) therapy for at least 3 months prior to screening and who plan to continue PAP therapy throughout the study.
  4. (BMI) ≥ 28 kg/m² at screening.
  5. Weight has been stable for 3 months prior to screening (body weight change \< 5%) (based on self-report).
  6. Participants of and their partners must have no plan for conception from screening until 6 months after completion of the trial, voluntarily use effective measures, and have no plan to donate sperm or oocytes within 6 months after trial completion.
  7. Willingness to provide written informed consent and strictly comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Known to the drug, its , or other drugs with similar pharmacological activity.
  2. Use of any of the following within 3 months prior to screening:

1) GLP-1 receptor agonists or similar drugs with the same target; 2) biguanides, SGLT-2 inhibitors, DPP-4 inhibitors, or any other hypoglycemic agents; 3) weight-influencing medications or anticipated use during the study (including systemic [excluding non-high-dose use \<7 days within 3 months prior to screening and planned use \<14 days during the study], tricyclic antidepressants, antipsychotics, mood stabilizers); 4) over-the-counter weight-loss drugs or appetite suppressants (including traditional Chinese medicine, health supplements, meal replacements), prescription weight-loss drugs (e.g., orlistat), or lipolytic injections; 5) stimulants, sedative-hypnotics, opioids, trazodone, or muscle relaxants; 6) over-the-counter or prescription medications that may affect excessive daytime sleepiness assessment.

3.History or evidence of any of the following diseases:

  1. . Diagnosed with type 1, type 2 diabetes mellitus or other types of diabetes mellitus (history of gestational diabetes mellitus excluded);
  2. . History of acute or chronic pancreatitis or pancreatic surgery;
  3. . History of symptomatic gallbladder disease within 1 year prior to screening (excluding participants who underwent cholecystectomy completed at least 3 months before screening without long-term complications); or gallstones and/or bile duct stones detected by abdominal ultrasound at screening, assessed by the investigator to require treatment, likely to require treatment during the study, or other gallbladder lesions judged by the investigator to potentially compromise participant safety;
  4. . Personal or family history (first-degree relatives: parents, children, siblings) of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);
  5. . Presence of endocrine disorders that may significantly affect body weight, e.g., Cushing's syndrome, pituitary-hypothalamic injury, hypogonadism; monogenic-obesity or hereditary obesity syndromes; obesity secondary to weight-loss medication reduction/discontinuation, long-term glucocorticoid, growth hormone or antipsychotic use;
  6. . History of bariatric surgery or planned bariatric surgery, acupuncture weight-loss treatment, liposuction or abdominal lipolysis during the study, except for:a) Acupuncture weight-loss therapy or liposuction (e.g., abdominal liposuction) performed >1 year prior to screening;b) Gastric band removed >1 year prior to screening;c) Intragastric balloon removed >1 year prior to screening;d) Duodenal-jejunal bypass sleeve removed >1 year prior to screening;
  7. . Previous history of depression, or Patient Health Questionnaire-9 (PHQ-9) score ≥15 at screening, or history of severe psychiatric disorders (including but not limited to suicidal ideation, schizophrenia, bipolar disorder);
  8. . Positive response to suicidal ideation questions 4 or 5, or any suicidal-behavior-related questions on the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening;
  9. . History of cardiovascular or cerebrovascular disease within 6 months prior to screening, defined as:a) Myocardial infarction (MI) or unstable angina;b) Cardiac-related surgery (including coronary artery bypass grafting, percutaneous coronary intervention);c) Congestive heart failure ( [NYHA] Class III-IV, see Appendix 2 for details);d) Cerebrovascular accident (old lacunar infarction excluded), including but not limited to hemorrhagic/ischemic stroke or ;e) Other cardiovascular or cerebrovascular diseases assessed by the investigator that render the subject ineligible for the trial;
  10. . Prior sleep-apnea-related surgery or major ENT surgery (including tonsillectomy, adenoidectomy), assessed by the investigator at screening to still influence the occurrence or severity of OSA; or planned sleep-apnea-related or major ENT surgery during the trial.

    Note: Participants with minor prior ENT surgery (e.g., septoplasty) may be considered eligible at the investigator's discretion.

  11. . History or presence at screening of clinically relevant medical conditions (other than OSA) or psychiatric disorders associated with insomnia or excessive daytime sleepiness;
  12. . Receipt of other active device therapies for OSA besides PAP (e.g., oral appliance) at screening, or other therapies that may interfere with study results per investigator judgment, unless the participant is willing to discontinue such therapies at screening and throughout the study;
  13. . Participants who are unable (per investigator judgment) or unwilling to discontinue PAP therapy for 7 days prior to PSG assessment;
  14. . History or presence of sleep disorders other than OSA, e.g., central or mixed sleep apnea with ≥50 % central/mixed events, or Cheyne-Stokes respiration;
  15. . Prior diagnosis of obesity hypoventilation syndrome or daytime hypercapnia;
  16. . Requirement for supplemental oxygen therapy;
  17. . Severe craniofacial bony deformities/abnormalities (e.g., micrognathia) significantly compromising the airway at screening; or other significant oral-cranio-maxillofacial or upper-airway anatomical abnormalities affecting breathing as judged by the investigator;
  18. . Presence of disorders related to gastric emptying impairment (e.g., gastroparesis, pyloric obstruction, intestinal obstruction), gastrointestinal diseases assessed by the investigator to increase post-dose risk (e.g., severe active ulcer, inflammatory bowel disease, acute gastroenteritis, uncontrolled gastroesophageal reflux disease) at screening; or history of major gastrointestinal surgery (excluding fully recovered procedures such as gastrointestinal polypectomy, appendectomy, cholecystectomy deemed safe for trial participation by the investigator);
  19. . of any organ system within the past 5 years, regardless of local recurrence or ; except for cured local basal-cell skin carcinoma, cervical carcinoma in-situ, prostate carcinoma in-situ, and radically resected breast ductal carcinoma in-situ with stable disease per investigator assessment;
  20. . Major surgery, severe trauma or severe infection within 1 month prior to screening, judged by the investigator to preclude study participation;
  21. . Concurrent diseases including respiratory, urinary, neurological, hematological, or immune-system disorders, judged by the investigator to compromise participant safety, efficacy evaluation or compliance.

4.Abnormal laboratory findings at screening meeting any of the following:

  1. . ≥6.5 % or fasting plasma glucose ≥7.0 mmol/L;
  2. . Hepatic or renal impairment: (ALT) and/or aspartate aminotransferase (AST) ≥3 × (ULN); total serum ≥1.5 × ULN; estimated (eGFR) \<30 mL/min/1.73 m² (calculated by CKD-EPI 2021 creatinine-Cystatin C formula, see Appendix 4);
  3. . Serum calcitonin ≥50 pg/mL (i.e., 50 ng/L);
  4. . Thyroid dysfunction uncontrolled on stable medication doses; or clinically significant abnormal thyroid function requiring initiation of treatment at screening; or thyroid-ultrasound-detected thyroid nodules with TI-RADS ≥4a (or ACR TI-RADS ≥TR4), or nodules likely to require fine-needle aspiration and/or surgery during the trial per investigator judgment;
  5. . Fasting triglycerides ≥5.6 mmol/L;
  6. . Serum amylase and/or lipase >2.0 × ULN;
  7. . \<90 g/L;
  8. . Untreated or poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg, based on the average of 3 blood-pressure measurements at screening);
  9. . Clinically significant (ECG) abnormalities including:

    a) Second- or third-degree atrioventricular block;b) Long- syndrome, or Fridericia-corrected QT (QTcF) >470 ms for female participants, >450 ms for male participants (calculation formula see Appendix 4);c) olff-Parkinson-White syndrome;d) Heart rate \<50 bpm or >110 bpm;e) Other severe arrhythmias requiring treatment;

  10. . Positive surface antigen with HBV-DNA above upper reference limit; or positive hepatitis-C antibody with above upper reference limit; or positive antibody; or dual positive syphilis-specific and non-specific antibodies;
  11. . Clinically significant abnormalities identified by physical examination, vital-sign assessment, laboratory testing, judged by the investigator to pose substantial risk to participants or interfere with safety and PK evaluations, rendering the subject unsuitable for the trial.

5.Participation in another interventional clinical trial within 3 months prior to screening (excluding subjects who only completed screening without enrollment, or enrolled but did not receive study treatment).

6.Blood loss ≥400 mL (including trauma, blood sampling, blood donation) or receipt of blood/blood-component transfusion within 3 months prior to screening.

7.History of drug or alcohol abuse within 3 months prior to screening; alcohol abuse defined as >7 standard drinks/week for females or >14 standard drinks/week for males (1 standard drink = 150 mL wine = 360 mL beer = 45 mL spirits).

8.Unable to tolerate venipuncture or history of needle/blood phobia. 9.Any other condition deemed unsuitable by the investigator.

Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    UBT251 Dose 1

    Participants will receive UBT251 subcutaneously (SC) .

    Drug: UBT251

  • Experimental
    UBT251 Dose 2

    Participants will receive UBT251 subcutaneously (SC) .

    Drug: UBT251

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

  • DrugUBT251

    Administered SC

  • DrugUBT251

    Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Apnea-Hypopnea Index (AHI)

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Percentage change from baseline in the AHI

    Time frame: Baseline, Week 52

  2. Proportion of participants with ≥50% reduction in Apnea-Hypopnea Index (AHI) from baseline

    Time frame: Baseline, Week 52

  3. Percentage change from baseline in body weight

    Time frame: Baseline, Week 52

  4. Percentage of participants with an AHI < 5 events/hour or an AHI ≥ 5 and ≤ 14 events/hour with an Epworth Sleepiness Scale (ESS) score ≤ 10

    Time frame: Baseline, Week 52

  5. Percentage of participants with a reduction in AHI ≥ 50% from baseline and a reduction in body weight ≥ 10% from baseline

    Time frame: Baseline, Week 20, Week 52

  6. Percentage change from baseline in Sleep-Apnea-Specific Hypoxic Burden (SASHB)

    Time frame: Baseline, Week 20, Week 52

  7. Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Short-Form 8a score

    range: 0 to 100 for both scales; higher scores indicate worse sleep-related impairment and worse sleep disturbance, respectively

    Time frame: Baseline, Week 20, Week 52

  8. Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short-Form 8b score

    range: 0 to 100 for both scales; higher scores indicate worse sleep-related impairment and worse sleep disturbance, respectively

    Time frame: Baseline, Week 20, Week 52

  9. Proportion of participants with improvement in EuroQol 5-Dimension 5-Level (EQ-5D-5L)

    range: 0 to 1; higher scores indicate better health-related quality of life

    Time frame: Baseline, Week 20, Week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2029, 29 months later.

Of 27 phase 3 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 32. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 8, 2026
StartEst.
Oct 10, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Apr 2029
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07806851
Responsible party
Sponsor
First posted
Sep 8, 2026
Start date
Oct 10, 2026 (estimated)
Primary completion
Mar 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Sep 8, 2026

Study contacts

Haiyan Zhang
Contact
zhanghy@tul.com.cn
+86 18998165570

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UBT251

Start the discussion